Chemomab Therapeutics Ltd - Company Profile

Powered by

All the sales intelligence you need on Chemomab Therapeutics Ltd in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Chemomab Therapeutics Ltd fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Chemomab Therapeutics Ltd.

Back to companies

Chemomab Therapeutics Ltd: Executives

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

The following section provides information on Chemomab Therapeutics Ltd’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into Chemomab Therapeutics Ltd's management and employees, unlock the full data with our company analytics monitoring tool.

Executives

Nissim Darvish

Chairman Executive Board Since: 2023 Age: 59

Mr. Nissim Darvish has been the Chairman of the company since 2023. Prior to this, he served as a Venture Partner at OrbiMed Israel and as a Director of Meters Biopharma Inc and Medigus Ltd. Previously, he served as the General Partner at Pitango Venture Capital. Mr. Darvish also served as the founder and the Chief Executive Officer of Impulse Dynamics.

Read Hide full bio of Nissim Darvish

Adi Mor, PhD

Chief Executive Officer; Chief Scientific Officer; Director Executive Board Since: 2011 Age: 43

Ms. Adi Mor has been the Chief Scientific Officer, Chief Executive Officer, and Director of the company since 2021. Prior to this, she served as the Chief Executive Officer and Co-founder of Chemomab Ltd., a wholly-owned subsidiary of the company.

Read Hide full bio of Adi Mor, PhD

Sigal Fattal

Chief Financial Officer Senior Management Since: 2021 Age: 54

Ms. Sigal Fattal has been the Chief Financial Officer of the company since 2021. Prior to this, she served as the Chief Financial Officer at BiomX. Previously, she served as the Chief Financial Officer at Evogene.

Read Hide full bio of Sigal Fattal

Jack Lawler

Chief Development Officer Senior Management Since: 2025

Mr. Jack Lawler has been the Chief Development Officer of the company since April 2025. Prior to this, he served as the Senior Vice President, Global Clinical Development Operations of the company. Previously, he served as the Vice President, Clinical Operations & Data Management at Goldfinch Bio.

Read Hide full bio of Jack Lawler

David M. Weiner, MD

Chief Medical Officer - Interim Senior Management Since: 2025

Dr. David M. Weiner has been the Interim Chief Medical Officer of the company since April 2025. Prior to this, he served as the Chief Scientific Officer and Director at AxoSIm. Previously, he served as the Interim Chief Medical Officer of the company. Mr. Weiner also served as the Chief Executive Officer of Amathus Therapeutics and Chief Medical Officer at Lumos Pharma.

Read Hide full bio of David M. Weiner, MD
Gain a 360-degree view of Chemomab Therapeutics Ltd and make more informed decisions for your business Gain a 360-degree view of Chemomab Therapeutics Ltd and make more informed decisions for your business Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer